AVITA Therapeutics Inc (ASX:AVH) revealed preliminary Q4 and FY20 results, together with a company update.
- In the fourth quarter, total global net revenue for the fourth quarter stood at US$3.88 million and total consolidated sales for FY20 (year ended 30 June 2020) were reported to be US$14.32 million.
- S. RECELL® System sales in Q4 and FY20 reported to be US$3.79 million and US$13.79 million, respectively.
- At the end of the fourth quarter, AVITA had cash and cash equivalents of nearly US$73.84 million.
AVH quoted at A$8.140 down by 4.46% at AEST 12:31 PM.
Penny stocks have been known to attract investors who are looking for explosive gains and it is possible to get lucky with these typically speculative investments. Just as the name suggests, penny stocks trade at low prices and are common shares of small public companies.
Get an exclusive insight into the features of penny stocks along with their pros and cons. Read about what you should be wary about when figuring out ways to invest in them, so that the possibility for big rewards does not tend to outweigh the risks.